Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Real-world Effectiveness and Treatment Sequences in Patients With Extensive Stage SCLC Who Received Lurbinectedin as Part of the French Early Access Program (ATU)

Next Previous
Trial Profile

Real-world Effectiveness and Treatment Sequences in Patients With Extensive Stage SCLC Who Received Lurbinectedin as Part of the French Early Access Program (ATU)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lurbinectedin (Primary)
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms LURBICLIN

Most Recent Events

  • 26 May 2023 According to PharmaMar media release, data from this study will be presented at the annual meeting of the American Society of Clinical Oncology (ASCO), to be held on June 2-6, 2023, both virtually and in situ in Chicago, USA.
  • 05 Jan 2023 Status changed from active, no longer recruiting to completed.
  • 28 Dec 2022 Planned End Date changed from 31 Dec 2022 to 31 Jan 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top